Aortic valve replacement for aortic stenosis: Influence of centre volume on TAVR adoption rates and outcomes in France.

Aortic stenosis Aortic valve replacement Centre volume Outcome

Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
12 Apr 2024
Historique:
received: 20 11 2023
revised: 19 02 2024
accepted: 20 02 2024
medline: 27 4 2024
pubmed: 27 4 2024
entrez: 26 4 2024
Statut: aheadofprint

Résumé

Transcatheter (TAVR) has supplanted surgical (SAVR) aortic valve replacement (AVR). To evaluate whether adoption of this technology has varied according to centre volume at the nationwide level. From an administrative hospital-discharge database, we collected data on all AVRs performed in France between 2007 and 2019. Centres were divided into terciles based on the annual number of SAVRs performed in 2007-2009 ("before TAVR era"). A total of 192,773 AVRs (134,662 SAVRs and 58,111 TAVRs) were performed in 47 centres. The annual number of AVRs and TAVRs increased significantly and linearly in low-volume (<152 SAVRs/year; median 106, interquartile range [IQR] 75-129), middle-volume (152-219 SAVRs/year; median 197, IQR 172-212) and high-volume (>219 SAVRs/year; median 303, IQR 268-513) terciles, but to a greater degree in the latter (+14, +16 and +24 AVRs/centre/year and +16, +19 and +31 TAVRs/centre/year, respectively; P In a centralized public healthcare system, the total number of AVRs increased linearly between 2007 and 2019, mostly due to an increase in TAVR, irrespective of centre volume. Progressive declines in patient risk profiles and death rates were observed in all terciles; in 2017-2019 death rates were similar in all terciles, although lower in high-volume centres for SAVR.

Sections du résumé

BACKGROUND BACKGROUND
Transcatheter (TAVR) has supplanted surgical (SAVR) aortic valve replacement (AVR).
AIM OBJECTIVE
To evaluate whether adoption of this technology has varied according to centre volume at the nationwide level.
METHODS METHODS
From an administrative hospital-discharge database, we collected data on all AVRs performed in France between 2007 and 2019. Centres were divided into terciles based on the annual number of SAVRs performed in 2007-2009 ("before TAVR era").
RESULTS RESULTS
A total of 192,773 AVRs (134,662 SAVRs and 58,111 TAVRs) were performed in 47 centres. The annual number of AVRs and TAVRs increased significantly and linearly in low-volume (<152 SAVRs/year; median 106, interquartile range [IQR] 75-129), middle-volume (152-219 SAVRs/year; median 197, IQR 172-212) and high-volume (>219 SAVRs/year; median 303, IQR 268-513) terciles, but to a greater degree in the latter (+14, +16 and +24 AVRs/centre/year and +16, +19 and +31 TAVRs/centre/year, respectively; P
CONCLUSIONS CONCLUSIONS
In a centralized public healthcare system, the total number of AVRs increased linearly between 2007 and 2019, mostly due to an increase in TAVR, irrespective of centre volume. Progressive declines in patient risk profiles and death rates were observed in all terciles; in 2017-2019 death rates were similar in all terciles, although lower in high-volume centres for SAVR.

Identifiants

pubmed: 38670869
pii: S1875-2136(24)00053-6
doi: 10.1016/j.acvd.2024.02.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

Nadav Willner (N)

Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada.

Virginia Nguyen (V)

Cardiology Department, Centre Cardiologique du Nord, 93200 Saint-Denis, France.

Graeme Prosperi-Porta (G)

Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada.

Helene Eltchaninoff (H)

Department of Cardiology, CHU de Rouen, U1096, Normandie Université, UNIROUEN, 76000 Rouen, France.

Ian G Burwash (IG)

Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada.

Morgane Michel (M)

Paris-Cité, 75006 Paris, France; Unité d'Épidémiologie Clinique, Hôpital Robert-Debré, AP-HP, 75019 Paris, France; U1123, Inserm, ECEVE, 75010 Paris, France.

Eric Durand (E)

Department of Cardiology, CHU de Rouen, U1096, Normandie Université, UNIROUEN, 76000 Rouen, France.

Martine Gilard (M)

Department of Cardiology, Brest University Hospital, 29200 Brest, France.

Christel Dindorf (C)

Paris-Cité, 75006 Paris, France; U1123, Inserm, ECEVE, 75010 Paris, France; URC Eco Île-de-France, Hôtel-Dieu, AP-HP, 75004 Paris, France.

Julien Dreyfus (J)

Cardiology Department, Centre Cardiologique du Nord, 93200 Saint-Denis, France.

Bernard Iung (B)

Paris-Cité, 75006 Paris, France; Department of Cardiology, Bichat Hospital, AP-HP, 75018 Paris, France; Inserm U1148, Bichat Hospital, AP-HP, 75018 Paris, France.

Alain Cribier (A)

Department of Cardiology, CHU de Rouen, U1096, Normandie Université, UNIROUEN, 76000 Rouen, France.

Alec Vahanian (A)

Paris-Cité, 75006 Paris, France; Inserm U1148, Bichat Hospital, AP-HP, 75018 Paris, France.

Karine Chevreul (K)

Paris-Cité, 75006 Paris, France; Department of Cardiology, Brest University Hospital, 29200 Brest, France; URC Eco Île-de-France, Hôtel-Dieu, AP-HP, 75004 Paris, France.

David Messika-Zeitoun (D)

Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada. Electronic address: DMessika-zeitoun@ottawaheart.ca.

Classifications MeSH